Haemophilus parasuis (Glaesserella parasuis) and Glässer's Disease in Swine: A Comprehensive Clinical Reference

Introduction

Haemophilus parasuis (recently reclassified as Glaesserella parasuis) is a Gram-negative, NAD-dependent coccobacillus that colonizes the upper respiratory tract of swine [1, 2]. Under conditions of stress or immunological naivety, it can breach mucosal barriers and cause systemic disease, most notably Glässer's disease, which is characterized by fibrinous polyserositis, polyarthritis, and meningitis [1, 3]. The bacterium is a major cause of morbidity and mortality in intensive pig production systems worldwide, particularly in post-weaning and nursery-age animals [2, 4].

Taxonomy and Nomenclature

The organism was originally classified within the genus Haemophilus based on its requirement for nicotinamide adenine dinucleotide (NAD, Factor V) but not hemin (Factor X) [1]. Subsequent phylogenetic analyses using 16S rRNA gene sequencing and whole-genome comparisons demonstrated that H. parasuis is distinct from other Haemophilus species, leading to its reclassification into the novel genus Glaesserella within the family Pasteurellaceae [2, 5]. The genus name honors the German veterinarian Karl Glässer, who first described the disease. Despite the taxonomic revision, the name Haemophilus parasuis remains widely used in clinical and diagnostic contexts [1, 4].

The bacterium is a commensal inhabitant of the nasal cavities and tonsils of healthy pigs, with colonization rates approaching 100% in many herds [3, 6]. Pathogenic and non-pathogenic strains coexist, and disease expression depends on host susceptibility, strain virulence, and environmental stressors [1, 4].

Microbiology and Biophysical Characteristics

Glaesserella parasuis is a small (0.2–0.5 μm x 0.5–2.0 μm), pleomorphic, non-motile, non-spore-forming rod [1, 3]. It is facultatively anaerobic and requires NAD (V factor) for growth, which can be supplied by other bacteria (satellite phenomenon) or supplemented in culture media [1, 2]. The organism does not require hemin (X factor), differentiating it from Haemophilus influenzae [1, 3]. Optimal growth occurs at 37°C in 5% CO2 on chocolate agar or supplemented trypticase soy agar [2, 4]. Colonies are small, smooth, translucent, and non-hemolytic after 24–48 hours [1, 3].

The cell wall lipooligosaccharide (LOS) is a major virulence determinant, with endotoxic properties contributing to the systemic inflammatory response [1, 5]. Capsular polysaccharides are present in virulent strains and are associated with serovar specificity [2, 6]. The bacterium is sensitive to dessication and survives poorly outside the host, with environmental persistence typically limited to less than 48 hours in organic matter [3, 4].

Epidemiology and Transmission

Transmission occurs primarily via direct contact with respiratory secretions from carrier animals [1, 2]. Aerosol spread over short distances within pens is also important [3, 4]. Vertical transmission from sows to piglets occurs early in life, with colonization of the upper respiratory tract established within the first few days [1, 5]. Disease typically manifests in weaned pigs aged 4–12 weeks, coinciding with waning maternal immunity and the stress of mixing, transport, and changes in diet [2, 4].

The prevalence of H. parasuis in pig populations worldwide is high, with multiple serovars often co-circulating within a herd [1, 3]. Outbreaks of Glässer's disease are commonly associated with introduction of new serovars or high-virulence strains into a naïve population, or with management practices that increase stress and respiratory disease burden (e.g., poor ventilation, overcrowding) [2, 6]. Concurrent infections with porcine reproductive and respiratory syndrome virus (PRRSV) or swine influenza virus predispose pigs to severe H. parasuis disease through immunosuppression and damage to the respiratory epithelium [1, 4, 5]. These comorbidities are discussed in the context of broader swine respiratory disease complexes, such as those described for Porcine Reproductive and Respiratory Syndrome and Streptococcus suis.

Serovars and Virulence Factors

To date, 15 serovars (1–15) have been identified based on immunodiffusion or coagglutination tests targeting capsular antigens [1, 3]. Serovars 1, 2, 4, 5, 10, 12, 13, and 14 are considered highly virulent, whereas serovars 3, 6, 7, 8, 9, and 11 are of low to intermediate virulence [2, 4]. Serovar 15 has variable pathogenicity [1, 5]. The classification of a given isolate into a serovar is essential for epidemiological tracking and for designing effective autogenous vaccines [2, 6]. Nontypeable isolates are frequently encountered and may represent low-virulence commensal strains [1, 3].

Table 1 summarizes the serovar classification and associated virulence in swine.

Table 1. Virulence classification of H. parasuis serovars based on clinical data [1, 2, 3, 4].

Key virulence factors include the lipooligosaccharide (LOS), which triggers a strong pro-inflammatory cytokine cascade (IL-1, TNF-α, IL-6), and surface proteins such as autotransporters and outer membrane proteins that mediate adhesion and invasion of host cells [1, 5]. The polysaccharide capsule of virulent serovars provides resistance to phagocytosis and complement-mediated killing [2, 6]. Fimbriae and other adhesins facilitate attachment to respiratory epithelial cells [3, 4].

Pathogenesis and Host Interactions

The pathogenesis of Glässer's disease begins with colonization of the upper respiratory tract via fimbrial and outer membrane protein interactions with porcine respiratory epithelial cells [1, 3]. Following mucosal invasion, the bacterium enters the bloodstream, causing bacteremia [2, 4]. The LOS induces systemic inflammation, leading to increased vascular permeability and fibrin exudation into serosal cavities [1, 5]. The organism localizes to the pleura, pericardium, peritoneum, joints, and meninges, where it triggers a robust fibrinous inflammatory response [2, 3].

The incubation period is typically 1–4 days after exposure under experimental conditions [1, 4]. The host immune response relies heavily on opsonizing antibodies (IgG and IgA) against capsular polysaccharides and LOS [3, 6]. Complement-mediated bacteriolysis and opsonophagocytosis by macrophages and neutrophils are critical for clearance [1, 5]. Pigs that survive infection develop serovar-specific immunity but remain susceptible to other serovars [2, 4].

Clinical Signs and Disease Syndromes

The clinical presentation of H. parasuis infection ranges from peracute death to chronic, subclinical carriage [1, 2]. In the peracute form, pigs may be found dead without premonitory signs, with death occurring within 4–6 hours of the onset of fever [2, 3]. Acute disease is characterized by pyrexia (40–42°C), anorexia, depression, huddling, and reluctance to move [1, 4]. Polyserositis manifests as dyspnea (due to pleuritis and pericarditis), abdominal tenderness (peritonitis), and joint swelling with lameness (polyarthritis) [2, 5]. Central nervous system signs, including ataxia, paddling, nystagmus, and recumbency, indicate meningitis [1, 3]. Chronic cases show reduced growth rates, persistent lameness, and signs of respiratory distress [2, 4].

The disease can be confused with other septicemic conditions, such as those caused by Streptococcus suis, Actinobacillus suis, or Mycoplasma hyorhinis [1, 5]. Differential diagnosis also includes Escherichia coli septicemia in neonates and Clostridium perfringens enterotoxemias, though these are less common in the age group affected by Glässer's disease [2, 4].

Pathological Findings

Gross lesions in acute Glässer's disease are dominated by fibrinous polyserositis [1, 3]. There is abundant fibrin deposition and turbid serosanguinous fluid in the pleural, pericardial, and peritoneal cavities [2, 4]. The joints, particularly the carpal, tarsal, and stifle joints, contain thickened synovial fluid with fibrin clots [1, 5]. Meningeal blood vessels are congested, and a fibrinopurulent exudate may cover the brain surface [2, 3].

Histopathological examination reveals a fibrinopurulent inflammatory exudate with neutrophils, macrophages, and fibrin on serosal surfaces [1, 4]. In the meninges, there is thickening due to neutrophil infiltration and fibrin deposition [2, 5]. The underlying brain parenchyma may show hemorrhage and perivascular cuffing [3, 4]. In chronic cases, fibrous adhesions develop between serosal layers, and articular cartilage erosion may be present [1, 6].

Laboratory Diagnosis

Definitive diagnosis of H. parasuis infection requires isolation of the organism from systemic sites (serosal exudate, joint fluid, cerebrospinal fluid) or from lung lesions in cases of bronchopneumonia [1, 3]. Nasal swabs are not recommended for disease diagnosis due to high carrier rates among healthy pigs [2, 4].

Culture and Isolation

Samples should be collected aseptically and transported to the laboratory in a suitable transport medium (e.g., Amies with charcoal) within 24 hours under refrigeration [1, 3]. The bacterium is fastidious and can be isolated on chocolate agar supplemented with NAD, incubated at 37°C in 5% CO2 for 24–48 hours [2, 4]. Satellite growth around a streak of Staphylococcus aureus (which supplies NAD) is a classic diagnostic feature [1, 5]. Colonies are smooth, translucent, and approximately 0.5 mm in diameter after 24 hours [2, 3]. Gram staining reveals pleomorphic Gram-negative rods and coccobacilli [1, 4].

Biochemical Identification

H. parasuis is oxidase-positive, catalase-positive, and produces acid from glucose and other carbohydrates without gas production [1, 3]. The X and V factor requirement test shows growth only around the V factor (NAD) disc, not the X factor disc [2, 4]. Commercial biochemical test strips or automated identification systems may misidentify the organism and should be interpreted with caution [1, 5].

Molecular Diagnostics

Polymerase chain reaction (PCR) assays targeting the 16S rRNA gene or specific virulence genes (e.g., infB, tbpA) are highly sensitive and specific for detecting H. parasuis directly from clinical specimens or from culture [1, 3, 4]. Quantitative real-time PCR (qPCR) allows estimation of bacterial load [2, 5]. Multilocus sequence typing (MLST) and serovar-specific PCR provide typing and epidemiological data [1, 6].

Serological Detection

Enzyme-linked immunosorbent assay (ELISA) kits are available for detection of antibodies against H. parasuis, but their utility for individual diagnosis is limited due to high background seroprevalence [1, 3]. Serology is more appropriate for herd-level monitoring, particularly to assess response to vaccination [2, 4].

Figure 1 illustrates a diagnostic decision tree for suspected Glässer's disease.

flowchart TD
    A[Pig with fever, polyserositis, lameness, or CNS signs] --> B{Antibiotic treatment history?}
    B -->|No recent antibiotics| C["Collect samples aseptically: synovial fluid, CSF, serosal exudate, lung"]
    B -->|Recent antibiotics| D[Collect same samples + EDTA blood for PCR]
    C --> E{Culture on chocolate agar + NAD}
    E -->|Growth in 24-48 h| F["Gram stain: Gram-negative coccobacilli"]
    F --> G[Satellite test / X&V factor test]
    G -->|V factor dependent| H[Biochemical or MALDI-TOF confirmation]
    H --> I[Serotyping by PCR or Co-agglutination]
    D --> J["DNA extraction + qPCR (16S rRNA/virulence gene")]
    J -->|Positive| I
    I --> K["Interpretation: confirm Glässer's disease"]
    E -->|No growth| L[Consider qPCR from original sample or test for other pathogens]
    L --> M[If qPCR positive, proceed to I]
    M --> K
    L --> N["If negative, consider other differentials: S. suis, mycoplasma, Actinobacillus"]

Figure 1. Diagnostic algorithm for suspected Glässer's disease in swine [1, 2, 3, 4, 5].

Treatment and Antimicrobial Therapy

Treatment of acute Glässer's disease requires early administration of antimicrobials with good tissue penetration, particularly into the central nervous system and joints [1, 3]. Parenteral administration (injectable) is preferred in anorectic pigs [2, 4]. Commonly used antimicrobial classes include penicillins (amoxicillin, ampicillin), cephalosporins (ceftiofur, cefquinome), tetracyclines, macrolides (tilmicosin, tulathromycin), fluoroquinolones (enrofloxacin, marbofloxacin), and potentiated sulfonamides (trimethoprim-sulfamethoxazole) [1, 3, 4, 5].

Antimicrobial susceptibility testing (AST) via disk diffusion or broth microdilution is strongly recommended for any outbreak to guide therapy and monitor resistance trends [1, 6]. Resistance to tetracyclines and macrolides has been reported in many regions [2, 4]. The Clinical and Laboratory Standards Institute (CLSI) has established veterinary breakpoints for H. parasuis against certain antimicrobials [1, 3].

In addition to antimicrobials, supportive care including provision of soft bedding, fluid therapy, and anti-inflammatory drugs (NSAIDs) improves recovery rates [2, 5]. Infeed or in-water mass medication (e.g., chlortetracycline or amoxicillin) may be used for outbreaks affecting an entire pen, though individual injection is preferred for severely affected animals [1, 4].

Control and Prevention

Control of Glässer's disease is based on a combination of management practices and immunization.

Management Measures

Reducing stress and improving environmental conditions are critical. Key interventions include:

• All-in/all-out production systems with thorough cleaning and disinfection between batches [1, 3].
• Optimal ventilation, temperature control, and stocking density in nursery and grow-finish barns [2, 4].
• Minimizing mixing of pigs from different sources and ages [1, 5].
• Early weaning (medicated early weaning or segregated early weaning) to reduce transmission from sows [3, 6].
• Elimination of concurrent infections (PRRSV, swine influenza, Mycoplasma hyopneumoniae) through vaccination or eradication programs [1, 2, 4].

Vaccination

Both commercial and autogenous (herd-specific) vaccines are available [1, 3]. Commercial bacterins typically include the most prevalent virulent serovars (e.g., 1, 2, 4, 5) but may not cover all serovars present in a given farm [2, 5]. Autogenous vaccines, prepared from local isolates, provide customized protection [1, 4]. Vaccination of sows (usually two doses pre-farrowing) confers passive immunity to piglets via colostrum [3, 6]. Piglets may also be vaccinated directly at 2–4 weeks of age, though maternal antibodies can interfere [1, 2].

Vaccine efficacy is serovar-specific; cross-protection between serovars is limited [1, 3]. Development of subunit vaccines based on highly conserved surface proteins is an area of active research [2, 4].

Public Health Significance

Haemophilus parasuis (Glaesserella parasuis) is considered non-zoonotic. No evidence exists of transmission to humans [1, 3]. This distinguishes it from other swine pathogens such as Streptococcus suis, which can cause serious disease in swine workers [1, 4]. For information on zoonotic bacteria of livestock origin, see Livestock Zoonoses: A Comprehensive Overview of Bacterial and Viral Diseases Transmitted from Farm Animals to Humans.

Conclusions

Haemophilus parasuis remains a significant cause of economic loss in pig production worldwide. Its fastidious growth requirements, multiplicity of serovars, and ability to synergize with viral respiratory pathogens complicate diagnosis and control. A thorough understanding of the microbiology, clinical presentation, and diagnostic options is essential for effective management of Glässer's disease in swine herds.

References

[1] Diseases of Swine (current edition). Wiley-Blackwell.

[2] Merck Veterinary Manual (current edition). Merck & Co., Inc.

[3] Veterinary Microbiology: Bacterial and Fungal Agents of Animal Disease. Saunders.

[4] Pathogenesis of Bacterial Infections in Animals. Wiley-Blackwell.

[5] Porcine Health Management: A Textbook for Veterinarians. 5M Publishing.

[6] Clinical Veterinary Microbiology. Mosby. *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.